What records are connected here?
- Evidence lanes
- 2
- Source years
- 8
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved1,6Evidence: Smaller human trialsNot a peptideMetabolic and weight · Brain, nerves and sleep
Also called NS23301
Not a peptide: a small molecule often looked up alongside peptides.
Tesofensine is a small synthetic drug, not a peptide: a triple monoamine reuptake inhibitor that blocks the uptake of noradrenaline, dopamine and serotonin by nerve cells. It was first studied for Parkinson and Alzheimer disease, then for obesity.1,2,5 In a 24-week randomized trial of 203 adults with obesity, published in 2008, people taking it lost 4.5% to 10.6% of their body weight, compared with 2.0% on placebo; in 2013 the journal published an expression of concern about that report.2,3 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,6,8
| Substance type | Not a peptide. FDA’s substance registry records tesofensine as a chemical compound with the formula C17H23Cl2NO, and trial reports describe it as a monoamine reuptake inhibitor.1,2 |
|---|---|
| What it is | A synthetic inhibitor of the reuptake of noradrenaline, dopamine and serotonin, also coded NS2330, recorded by FDA’s substance registry as a chemical compound.1,2 |
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,6 |
| Human evidence | Phase 2 randomized trials: one in 203 adults with obesity, and trials in Parkinson and Alzheimer disease whose weight data were pooled.2,4,5 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Tesofensine is a synthetic chemical compound, not a peptide. FDA’s substance registry records it with the formula C17H23Cl2NO and the code name NS2330.1
Researchers describe it as an inhibitor of the uptake of noradrenaline, dopamine and serotonin by nerve cells, a so-called triple monoamine reuptake inhibitor.2,5
It blocks the presynaptic uptake of noradrenaline, dopamine and serotonin, three chemical messengers in the brain, according to the 2008 trial report.2
A pooled analysis of weight data from its Parkinson and Alzheimer disease trials found weight loss, and its authors wrote that it was then being developed for obesity.4
A 2008 randomized, double-blind trial assigned 203 adults with obesity, all on a reduced-calorie diet, to one of three strengths of tesofensine or placebo for 24 weeks. Average weight loss was 4.5%, 9.2% and 10.6% with tesofensine and 2.0% with placebo; heart rate rose by about 7 beats per minute at the middle strength.2
The most common side effects in that trial were dry mouth, nausea, constipation, diarrhoea and insomnia. The authors said the results needed confirmation in phase 3 trials.2
In 2013 The Lancet published an expression of concern about the 2008 report.3
In four randomized trials in Parkinson or Alzheimer disease, people on tesofensine lost up to about 3% of their weight over 14 weeks without any diet program, and heart rate rose with strength, according to a pooled analysis.4
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of tesofensine by FDA.1,6
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list tesofensine.6
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Tesofensine is not among them.7,8
Whether its effect on weight holds up in larger, longer trials: the sources reviewed here describe phase 2 trials of up to 24 weeks, and the main obesity report is subject to an expression of concern.2,3
Its effect on the heart over time, since the trials reported a rise in heart rate.2,4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Tesofensine: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Tesofensine are a bounded selection, not every registration or paper about Tesofensine. For the years before Tesofensine was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Tesofensine as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Tesofensine in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; studied in clinical trials. A 24-week trial in 203 adults with obesity reported weight loss, but the journal later published an expression of concern about the report. Tesofensine is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; studied in clinical trials. A 24-week trial in 203 adults with obesity reported weight loss, but the journal later published an expression of concern about the report. Tesofensine is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date September 3, 2026
Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine.↗Source date September 3, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT03149445↗Source date February 26, 2024Literature metadata · added November 16, 2026
Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.↗Source date October 20, 2021PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
7 of 7 selected trial records include at least one phase value; 7 of 7 include a status value in the retained structured contract.
4 of 4 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00006077 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was tesofensine.
PeptideScanner retained ClinicalTrials.gov record NCT00394667 at 2026-11-16T17:29:46.323Z. Its registry update date was 2013-04-22, and PeptideScanner's reviewed identity mapping was tesofensine.
PeptideScanner retained ClinicalTrials.gov record NCT00428415 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-05, and PeptideScanner's reviewed identity mapping was tesofensine.
4 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span March 4, 2008 to September 3, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 42320973 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-06-19 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03149445 at 2026-11-16T17:29:46.323Z. Its registry update date was 2024-02-26, and PeptideScanner's reviewed identity mapping was tesofensine.↗
Literature metadata
PubMed lists PMID 17982477 in British journal of pharmacology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-11-05 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 19705923 in Clinical pharmacokinetics as Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02737891 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03286829 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine.↗
Literature metadata
PubMed lists PMID 17324246 in British journal of clinical pharmacology as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-02-23 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00394667 at 2026-11-16T17:29:46.323Z. Its registry update date was 2013-04-22, and PeptideScanner's reviewed identity mapping was tesofensine.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00481104 at 2026-11-16T17:29:46.323Z. Its registry update date was 2011-07-04, and PeptideScanner's reviewed identity mapping was tesofensine.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00428415 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-05, and PeptideScanner's reviewed identity mapping was tesofensine.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00006077 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was tesofensine.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
The Lancet · Official source · Source checked November 16, 2026
The Lancet · Official source · Source checked November 16, 2026
Obesity · Official source · Source checked November 16, 2026
Archives of Neurology · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026